← Research library

Prostatilen AC: Phase IV placebo-controlled study of sperm DNA fragmentation

Randomized study in people · 2022

What was studied
90 men aged 25–45 with infertility and elevated sperm DNA fragmentation, randomized 45:45 from 183 screened.
Main finding
Sperm DNA fragmentation was lower after the first 10-day course with Prostatilen AC versus placebo (p = 0.000022). After a second course, medians were 6.91% in the two-active-course group and 14.56% in the placebo-then-active group.

Sperm DNA fragmentation after course 1 · Median 10.23% (IQR 8.12–17.90) with Prostatilen AC. · Lower than placebo by the reported rank test. · p = 0.000022 between groups

Reported findings and study design

Double-blind, parallel, multicenter Phase IV study. Men received one 30 mg + 180 mg rectal suppository daily or matching placebo for 10 days. After a 21-day interval both arms received 10 days of active drug. DNA fragmentation was assessed using the TUNEL assay.

Population or model 90 men aged 25–45 with infertility and elevated sperm DNA fragmentation, randomized 45:45 from 183 screened.

Results · Original journal PDF, trial flow, methods and results
MeasureResultComparison, timing and statistics
Sperm DNA fragmentation after course 1Median 10.23% (IQR 8.12–17.90) with Prostatilen AC.Lower than placebo by the reported rank test. · p = 0.000022 between groups
Sperm DNA fragmentation after course 2Median 6.91% (IQR 4.91–11.30) after two active courses.14.56% (IQR 13.96–16.50) after placebo then an active course. · p = 0.00004 between groups
Seminal plasma antiradical activityReported between-group difference of +6.72% after course 1 and +23.7% after course 2.p = 0.02 and p = 0.0049, respectively
Adverse events and PSA12 reports of tenesmus or anal burning in 10 participants, with no treatment withdrawal or dosing change. The authors reported stable prostate-specific antigen.

Source for these results ↗ · Reviewed 2026-11-16

Study limitations and source details

Study limitations

  • Both groups received active treatment in the second course. That comparison estimates the difference between two courses and one course.
  • The trial evaluates a prostate extract and zinc-complex formulation, with no extract-only or zinc-only comparator. It measured semen markers and leaves pregnancy and live birth outcomes unanswered.

Source details

Original journal report

Original journal PDF, recruitment, treatment sequence, adverse events and Figures 1–3.

Sources checked

Citation

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Published

Randomized trialFull text available

I. B. Yakovlev, S. V. Teplykh, M. A. Rybalov, S. Yu. Borovets, V. B. Vasilyuk, M. V. Faraponova, A. A. Krasnov, S. V. Petlenko, V. A. Apryatina. Prostatilen AC: Phase IV placebo-controlled study of sperm DNA fragmentation Experimental and Clinical Pharmacology. 2022;85(2):11–15.

Study source ↗ · DOI 10.30906/0869-2092-2022-85-2-11-15 · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards